High dose chemotherapy with stem cell rescue for breast cancer: Current status and future directions

Breast Disease

Volumn 14, Issue , 2001, Pages 51-68

  Elias, A D ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Breast cancer; Hematopoietic stem cell support; High dose chemotherapy; Review; Transplant

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOXANTRONE; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; THIOTEPA; VINCRISTINE;

ARTICLE; BONE MARROW RESCUE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RESEARCH; CANCER STAGING; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG MEGADOSE; HUMAN; METASTASIS; MULTIMODALITY CANCER THERAPY; PATIENT CARE; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; TREATMENT PLANNING;

EID: 0035676334     PISSN: 08886008     EISSN: None     Source Type: Journal    
DOI: 10.3233/BD-2001-14107     Document Type: Article

References (99)

1. The PARMA international randomized study in relapsed non-Hodgkin's lymphoma: Analysis on the first 153 preincluded patients
2. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
3. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
4. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid
5. Dose-intensive chemotherapy in refractory gem cell cancer - A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation
6. High dose chemotherapy with autologous transplantation for persistent, relapsed ovarian cancer: A multivariate analysis of survival for 100 consistently treated patients
7. Dose intensive therapy for limited stage small cell lung cancer: Long-term outcome
8. 3d Modulation of antitumor alkylating agents (AA)
9. Combination chemotherapy, dose, and schedule
10. Phase III trial of doxorubicin versus paclitaxel versus doxorubicin plus paclitaxel as first-line therapy for metastatic breast cancer: An intergroup trial
11. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
12. Patient selection in high-dose chemotherapy trials: Relevance in high-risk breast cancer
13. Conventional- vs. high-dose therapy for metastatic breast cancer: Comparison of Cancer and Leukemia Group B (CALGB) and Blood and Marrow Transplant Registry (ABMTR) patients
14. Dose-response effect of adjuvant chemotherapy in breast cancer
15. The importance of dose-intensity in chemotherapy of metastatic breast cancer
16. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: The results of a randomized trial
17. Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial
18. Evaluation of the importance and relevance of dose intensity using epirubicin and cyclophosphamide in metastatic breast cancer: Interim analysis of a prospective randomized trial
19. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group
20. A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer
21. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer - Results from CALGB 9342
22. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America
23. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem cell support for advanced breast cancer
24. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer
25. Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high dose therapy with autologous stem-cell support
26. High-dose versus standard chemotherapy in metastatic breast cancer: Comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry
27. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomized trial
28. Primary high-dose chemotherapy for metastatic breast cancer: Update and analysis of prognostic factors
29. High dose chemotherapy with hematopoietic stem cell transplantation for metastatic breast cancer: Results of the French protocol PEGASE 04
30. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer
31. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous bone marrow support in women with measurable advanced breast cancer responding to standard-dose therapy
32. High-dose consolidation therapy with autologous stem cell rescue in stage IV breast cancer: Follow-up report
33. A large, prospective, randomized trial of high-dose combination alkylating agent (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving doxorubicin-based induction therapy (AFM)
34. Improved survival with consolidation high-dose cyclophosphamide, cisplatin, and carmustine (HD-CPB) compared with observation followed by transplant at relapse in women with metastatic breast cancer (MBC) and treated with induction Adriamycin, 5-fluorouracil, and methotrexate (AFM): A phase III prospective randomized comparative trial
35. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV patients with minimal metastatic disease
36. Immunohistochemical and pathologi factors predicting progression-free survival (PFS) and overall survival (OS) following high-dose chemotherapy (HDCT) and stem cell rescue (SCR) for responsive metastatic breast cancer
37. High-dose chemotherapy with haemoatopoietic rescue in breast cancer
38. Relationship of number of positive axillary nodes to the prognosis of patients with primary breast cancer: An NSABP update
39. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer
40. Improved disease-free (PFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with breast cancer (BC)
41. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
42. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
43. Results of a randomized trial of adjuvant chemotherapy with FEC50 vs FEC100 in high node-positive breast cancer patients
44. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: Findings from the National Surgical Adjuvant Breast and Bowel Project B-22
45. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
46. High-dose chemotherapy with autologous peripheral blood progenitor cell support for primary breast cancer in patients with 4-9 involved axillary lymph nodes
47. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer
48. Five year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥ 10 axillary lymph nodes (Duke/CALGB 8782)
49. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary nodes
50. Efficacy, toxicity and applicability of high-dose chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: Five-year results
51. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results
52. High-dose multimodality therapy with autologous stem cell support for stage IIIB breast cancer
53. Predictive model for relapse after high-dose chemotherapy with peripheral blood progenitor cell support for high-risk primary breast cancer
54. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation
55. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (>10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic support following standard-dose adjuvant therapy
56. Randomised trial of high-dose chemotherapy and haematopoietic progenitor-cell support in operable breast cancer with extensive axillary involvement
57. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma
58. A prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: Preliminary results of 9114/NCIC MA-13
59. Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy
60. Critique of the high-dose chemotherapy studies in breast cancer: A positive look at the data
61. Randomized phase III trial of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes
62. A Phase I trial of double transplant for metastatic breast cancer: Sequence and interval considerations
63. Double high-dose chemotherapy with stem cell rescue (HD-SCR) in patients with breast cancer - Effect of sequence
64. The interval between courses of high-dose chemotherapy with stem cell rescue: Therapeutic hypotheses
65. A preclinical model for sequential high dose chemotherapy
66. Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer: A feasibility study
67. Double dose-intensive chemotherapy with autologous stem cell support for metastatic breast cancer: No improvement in PFS by the sequence of high-dose melphalan followed by CTCb
68. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support
69. Tandem autotransplantation for the treatment of metastatic breast cancer
70. Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer
71. Rapidly cycled courses of high-dose chemotherapy supported by filgrastim and peripheral blood progenitors in patients with metastatic breast cancer
72. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer
73. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer
74. Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer
75. The Impact of Induction Duration and the Number of High Dose Cycles on the Long-term Survival of Women with Metastatic Breast Cancer Treated with High Dose Chemotherapy with Stem Cell Rescue: An Analysis of Trials from the Dana-Farber/Beth/Israel STAMP Program
76. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naïve metastatic breast cancer
77. A Short Course of Induction Chemotherapy Followed by Two Cycles of High-Dose Chemotherapy with Stem Cell Rescue for Chemotherapy Naïve Metastatic Breast Cancer: The Effect of Sequence
78. The relationship between high-dose treatment and combination chemotherapy: The concept of summation dose intensity
79. Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum (II)
80. Acute in vivo resistance in high-dose therapy
81. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines
82. Characterization of RAD9 of saccharomyces cerevisiae and evidence that its function acts post-translationally in cell cycle arrest after DNA damage
83. Genes involved in the G2 check point modulate the cell sensitivity to cisplatin
84. G2 phase cell cycle disturbance as a manifestation of genetic cell damage
85. G2 delay induced by nitrogen mustard in human cells affects cyclin A/cdk2 and cyclin B1/cdc2-kinase complexes differently
86. Cytokinetics
87. Duration of therapy in adjuvant chemotherapy trials
88. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer
89. Occult tumor contamination of hematopoietic stem-cell product does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer
90. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support
91. The prognostic value of bone marrow micrometastases in stage II/III breast cancer patients undergoing autologous transplant (ABMT) therapy
92. Prognostic significance of contaminating tumor cell in apheresis in high-risk breast cancer patients treated with peripheral blood stem cell transplantation
93. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer
94. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer
95. Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous hematopoietic stem cell support (ASCS) in patients with refractory metastatic breast cancer
96. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells
97. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer